



Imape

1642

WILLIAMS, MORGAN & AMERSON, P.C.

10333 RICHMOND, STE. 1100, HOUSTON, TEXAS 77042

(713) 934-7000 FAX: (713) 934-7011

Danny L. Williams
Terry D. Morgan
J. Mike Amerson
Kenneth D. Goodman
Jeffrey A. Pyle
Jaison C. John
Ruben S. Bains
Scott F. Diring

Shelley P.M. Fussey, Ph.D.*
Mark D. Moore, Ph.D.*
Raymund F. Eich, Ph.D.*
Daren C. Davis*
Stephanie A. Wardwell, Ph.D.*
Mark W. Sincell, Ph.D.*

*Patent Agent

WRITER'S DIRECT DIAL:
713.934.4079

January 26, 2004

FILE: 3999.002587

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

January 26, 2004

Date

Shelley P.M. Fussey

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: *U.S. Patent Application Serial No. 10/738,404; Entitled "Ant-VEGF Antibody Prodrug Methods (As Amended)"; Inventors: Thorpe and Brekken; Client Reference: UTSD:1412--8*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, PTO-Form 1449 and copy of References C88-C93.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Director is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/3999.002587

WILLIAMS, MORGAN & AMERSON, P.C.

Commissioner for Patents

January 26, 2004

Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

Encls.



CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

January 26, 2004

Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG
METHODS (As Amended)

Group Art Unit: 1642

Examiner: Yaen, C.

Atty. Dkt. No.: 3999.002587

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be required in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002587.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: January 26, 2004

Form PTO-1449 (modified)

JAN 28 2004

Atty. Docket No.

3999.002587

Serial No.

10/738,404

List of Patents and Publications for Applicant:

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Thorpe and Brekken

Filing Date:

December 17, 2003

Group:

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C88	De Bandt <i>et al.</i> , "Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI) but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis," <i>J. Immunol.</i> , 171:4853-4859, 2003.
	C89	LeCouter <i>et al.</i> , "Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1," <i>Science</i> , 299:890-893, 2003
	C90	Maes <i>et al.</i> , "Soluble VEGF Isoforms are Essential for Establishing Epiphyseal Vascularization and Regulating Chondrocyte Development and Survival," <i>J. Clin. Invest.</i> , 113:188-199, 2004.
	C91	Pipp <i>et al.</i> , "VEGFR-1-Selective VEGF Homologue PlGF is Arteriogenic Evidence for a Monocyte-Mediated Mechanism," <i>Circ. Res.</i> , 92:1-9, 2003.
	C92	Qi <i>et al.</i> , "A Novel Function for Tissue Inhibitor of Metalloproteinases-3 (TIMP3): Inhibition of Angiogenesis by Blockage of VEGF Binding to VEGF Receptor-2," <i>Nature Medicine</i> , 9(4):407-415, 2003.
	C93	Shih <i>et al.</i> , "Selective Stimulation of VEGFR-1 Prevents Oxygen-Induced Retinal Vascular Degeneration in Retinopathy of Prematurity," <i>J. Clin. Invest.</i> , 112:50-57, 2003.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)